Fig. 8: CD36 reversed the phenotype induced by BCL6 overexpression.

A A Schedule of manipulating the overexpression of CD36 and BCL6. Six-week-old mice were injected with AAV-Control, AVV-BCL6, AAV-Control + AAV-CD36, or AAV-BCL6 + AAV-CD36 via the tail vein and fed an HFD. B Protein level of CD36 and BCL6 in livers of the mice from the indicated groups after being injected with AAV. C Bodyweight, (D) food intake, and (E) LW/BW of the mice from the indicated groups (n = 6/group). F Representative images of H&E and Oil red O staining of liver tissues from the mice from the indicated groups. Scale bar, 100 μm. G Total cholesterol, H triglyceride, I NEFA, J ALT, and (K) AST levels in the livers from the mice of indicated groups fed an HFD for 16 weeks. (n = 6/group). L Representative images of immunohistochemistry staining of F4/80 of liver tissues from four group mice. Scale bar, 100 μm. M Protein level of CD36 and BCL6 in LO2 cells after transfected adv-Control, adv-BCL6, adv-Control + adv-CD36, or adv-BCL6 + adv-CD36. N Representative images of Oil red O staining of LO2 cells of indicated groups stimulated with PA (0.3 mM) for 24 h. Data represent the mean ± SEM, *P < 0.05, **P < 0.01, ***P < 0.001 and n.s. indicates no significance between the two indicated groups.